Brief: Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311
06/10/2025 12:13
Oct 6 (Reuters) - Invivyd Inc IVVD.O: INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID INVIVYD INC: DECLARATION AND LIBERTY CLINICAL TRIALS EXPECTED TO BEGIN AROUND YEAR-END 2025; TOP-LINE DATA ANTICIPATED MID-2026 INVIVYD INC - PLANS TRIAL START BY YEAR-END 2025, TOP-LINE DATA MID-2026 Source text: ID:nGNX1mjbc9 Further company coverage: IVVD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview